The__O assessment__O of__O cost-effectiveness,__O primarily__O undertaken__O by__O Buxton__B-ORG and__O colleagues,__O was__O a__O major__O part__O of__O the__O evidence__O provided__O by__O the__O MASS__B-ORG trial.__O
This__O underpinned__O policies__O and__O guidelines__O that__O introduced__O and__O promoted__O AAA__B-ORG screening__O in__O the__O UK__B-LOC and__O internationally.__O
AAAs__O affect__O more__O than__O 4%__O of__O British__B-MISC men__O aged__O 65-74__O and__O are__O responsible__O for__O over__O 6,800__O deaths__O annually.__O
The__O MASS__B-MISC trial__O showed__O that__O screening__O could__O reduce__O AAA-related__B-ORG mortality__O by__O 42%.__O
Implementation__O of__O the__O NHS__B-ORG AAA__I-ORG screening__O programme__O in__O started__O in__O 2009.__O
It__O was__O fully__O implemented__O in__O England__B-LOC by__O Spring__O 2013,__O offering__O `screening__O to__O around__O 300,000__O men__O every__O year__O during__O the__O year__O they__O turn__O 65'__O (1).__O
Uptake__O in__O the__O 2011-12__O cohort__O of__O men__O invited__O for__O screening__O was__O 75%,__O according__O to__O the__O latest__O report__O (1).__O
In__O 2008__O the__O Department__B-ORG of__I-ORG Health's__I-ORG (DH's)__I-ORG Impact__I-ORG Assessment__I-ORG considered__O policy__O options__O for__O AAA__B-ORG screening__O and__O estimated__O that__O each__O would__O provide__O a__O gain__O of__O at__O least__O 130,000__O quality__O adjusted__O life__O years__O (QALYS)__B-ORG over__O a__O 20__O year__O period,__O and__O that__O the__O net__O value__O of__O the__O option__O adopted__O was__O &#163;3,884million__O over__O 20__O years,__O valuing__O the__O health__O benefit__O at__O a__O social__O value__O of__O &#163;40,000__O per__O QALY__B-ORG gained__O (p.3)__O (2).__O
The__O ministerial__O commitment__O to__O introduce__O a__O national__O AAA__B-ORG screening__O policy__O was__O announced__O in__O 2008__O as__O part__O of__O a__O statement__O by__O the__O UK__B-ORG Prime__O Minister__O on__O the__O changes__O that__O would__O be__O made__O in__O what__O was__O the__O sixtieth__O year__O of__O the__O NHS__B-ORG (3).__O
The__O timescales__O throughout__O the__O UK__B-LOC varied__O slightly.__O
The__O decision__O to__O introduce__O a__O national__O screening__O programme__O in__O England__B-LOC had__O to__O be__O subject__O to__O an__O Impact__O Assessment__B-MISC produced__O by__O the__O DH,__B-ORG and__O signed__O off__O by__O the__O relevant__O minister__O (2).__O
Published__O in__O July__O 2008__O it__O explored__O the__O options__O and__O explained__O why__O the__O preferred__O option__O was__O a__O screening__O policy__O for__O all__O men__O aged__O 65.__O
Major__O evidence__O references__O used__O in__O the__O Impact__B-MISC Assessment__I-MISC were__O the__O four__O RCTs__O included__O in__O the__O Cochrane__B-MISC review,__O but__O especially__O the__O findings__O from__O the__O MASS__B-ORG trial.__O
The__O DH's__O Impact__O Assessment's__O analysis__O of__O costs__O relied__O heavily__O on__O work__O primarily__O led__O by__O HERG__O in__O the__O MASS__B-MISC study:__I-MISC Buxton__I-MISC et__I-MISC al__I-MISC (2002),__I-MISC Kim__I-MISC et__I-MISC al__I-MISC (2007).__O
Highlighting__O the__O importance__O of__O MASS,__B-ORG the__I-ORG Impact__I-ORG Assessment__I-ORG stated:__O `The__O main__O elements__O of__O the__O cost__O analysis__O are__O therefore__O based__O on__O the__O outputs__O and__O subsequent__O analysis__O from__O MASS....The__B-ORG unit__O costs__O for__O screening__O and__O elective__O and__O emergency__O surgery__O operations__O are__O based__O on__O MASS__O trials....An__O alternative__O cost__O base__O ...__O was__O also__O considered.__O
However,__O the__O MASS__B-ORG unit__O costs__O are__O more__O comprehensive__O and__O reliable,__O and__O are__O based__O on__O a__O detailed__O bottom-up__O costing,__O taking__O into__O account__O patient-specific__O costs.'__O
(paras__O 44,__O 48)__O (3).__O
Further__O evidence__O to__O support__O the__O importance__O of__O the__O MASS__B-ORG study,__O and__O HERG's__B-ORG contribution,__O in__O the__O policy__O decisions__O to__O set__O up__O a__O national__O screening__O programme__O comes__O from__O the__O DH__B-ORG and__I-ORG MRC.__I-ORG
The__B-ORG DH__I-ORG sent__O a__O letter__O on__O 15__O June__O 2011__O congratulating__O HERG__O on__O the__O work__O for__O Policy__B-ORG Research__I-ORG Programme:__I-ORG `This__I-ORG has__O made__O a__O significant__O contribution__O to__O strengthening__O the__O evidence-base__O for__O policymaking__O through__O a__O range__O of__O applied__O economic__O research.__O
This__O has__O included__O important__O contributions__O to__O the__O consideration__O of__O abdominal__O aortic__O aneurysm__O (AAA)__B-ORG screening;'__O (DH,__B-ORG Head__I-ORG of__I-ORG Policy__I-ORG Research__I-ORG Programme)__I-ORG (4).__O
In__O 2010__O the__O MRC__B-ORG reported__O on__O findings__O from__O its__O first__O collection__O of__O data__O on__O research__O impacts.__O
The__O impact__O of__O the__O MASS__B-MISC stream__O of__O work__O on__O the__O introduction__O of__O the__O national__O AAA__B-ORG screening__O programme__O was__O one__O of__O just__O eight__O examples__O of__O policy__O impact__O that__O the__O MRC__B-ORG highlighted__O (5).__O
To__O get__O to__O the__O position__O in__O 2008__O where__O ministers__O announced__O the__O decision__O to__O introduce__O the__O screening__O policy,__O Buxton__B-ORG and__O other__O MASS__B-ORG team__O members__O had__O undertaken__O extensive__O dissemination__O of__O the__O findings,__O both__O to__O the__O National__B-ORG Screening__I-ORG Committee,__I-ORG which__O analysed__O the__O data__O and__O options__O in__O detail,__O and__O also__O to__O relevant__O clinicians.__O
Following__O the__O contribution__O made__O by__O Buxton__O to__O the__O AAA__B-ORG screening__O decision,__O he__O was__O invited__O to__O become__O a__O member__O of__O the__O UK__B-ORG National__I-ORG Screening__I-ORG Committee__I-ORG from__O 2009.__O
On__O 31__O March__O 2004__O Buxton__O and__O others__O addressed__O many__O stakeholders__O at__O a__O meeting,__O `Aneurysm__B-ORG Screening:__I-ORG The__I-ORG Facts__I-ORG and__I-ORG the__I-ORG Future'__I-ORG called__O by__O the__O Vascular__B-ORG Surgical__I-ORG Society__I-ORG of__O Great__B-LOC Britain__I-LOC and__O Ireland.__B-LOC
It__O was__O widely__O covered__O by__O UK__B-ORG TV__I-ORG and__O print__O media,__O and__O the__O proceedings__O were__O published__O (6).__O
In__O addition__O to__O documented__O evidence__O of__O influence__O on__O health__O policy,__O and__O cost-effective,__O improved__O health__O services__O and__O clinical__O outcomes__O in__O the__O UK,__B-MISC the__I-MISC MASS__I-MISC trial__O also__O had__O extensive__O international__O impact__O on__O advisory__O committees,__O guidelines,__O and__O policies__O and__O helped__O generate__O improvements__O in__O both__O publicly__O and__O privately__O funded__O healthcare__O services.__O
This__O includes__O in__O the__O USA__B-LOC and__O Europe.__B-LOC
A__O 2009__O practice__O guideline__O from__O the__O US__B-ORG Society__I-ORG for__O Vascular__B-ORG Surgery__I-ORG drew__O on__O the__O same__O four__O studies__O as__O the__O Cochrane__B-ORG review,__O and__O so__O again__O the__O MASS__B-ORG study,__O contributing__O 67,800__O of__O the__O 127,891__O men__O included,__O had__O the__O most__O influence.__O
The__O guideline__O stated:__O `We__O recommend__O one-time__O ultrasound__O screening__O for__O AAA__B-ORG for__O all__O men__O at__O or__O older__O than__O age__O 65'__O (p.11S).__O
It__O described__O the__O level__O of__O recommendation__O as__O `Strong'__O and__O the__O quality__O of__O evidence__O as__O `High'__O (7).__O
AAA__B-ORG screening__O is__O now__O widely__O available__O in__O the__O USA.__B-LOC
Many__O of__O the__O policies__O and__O practices__O in__O the__O period__O from__O 2008__O drew__O on__O a__O key__O 2005__O evidence__O synthesis__O and__O Recommendation__B-PER Statement__I-PER from__O the__O US__B-ORG Preventive__I-ORG Services__I-ORG Task__I-ORG Force__I-ORG in__O its__O public__O advisory__O role.__O
The__O MASS__O study's__O importance__O was__O highlighted__O in__O both__O the__O recommendation__O and__O the__O synthesis,__O which__O have__O remained__O in__O place__O throughout__O 2008-13.__O
The__O latter__O stated:__O `the__O detailed__O micro-costing__O approach__O used__O in__O the__O MASS__B-MISC CEA...__I-MISC justified__O a__O "good"__O quality__O rating.'__O
(p.3)__O (8).__O
That__O review__O formed__O the__O basis__O both__O for__O the__O legislation__O under__O which__O Medicare__B-MISC has__O offered__O AAA__B-ORG screening__O throughout__O the__O 2008-13__O period,__O and__O for__O clinical__O policy__O statements__O issued__O by__O the__O healthcare__O companies,__O such__O as__O Aetna__B-ORG which__O for__O its__O 22__O million__O members__O says:__O `Aetna__B-ORG considers__O one-time__O ultrasound__O screening__O for__O abdominal__O aortic__O aneurysms__O (AAA)__B-ORG medically__O necessary__O for__O men__O 65__O years__O of__O age__O or__O older.'__O
(8).__O
Originally__O published__O in__O 2005__O the__O policy__O was__O reviewed__O annually__O and__O republished,__O the__O last__O time__O being__O in__O December__O 2012,__O and__O continues__O to__O inform__O healthcare__O practice.__O
In__O Sweden,__B-MISC health__O policy__O is__O decided__O by__O counties.__O
An__O assessment__O by__O the__O Swedish__B-ORG Council__I-ORG on__I-ORG Health__I-ORG Technology__I-ORG Assessment__I-ORG (SBU)__I-ORG in__O 2008__O came__O after__O some__O counties__O had__O introduced__O screening.__O
But__O it__O strongly__O recommended__O screening__O and__O drew__O heavily__O on__O `The__O largest__O study,__O the__O MASS__B-ORG study'__O (p.2),__O showing__O over__O 50%__O of__O the__O men__O in__O the__O review__O came__O from__O the__O MASS__B-ORG study__O (9).__O
Screening__O was__O later__O adopted__O by__O most__O counties.__O
The__O 2011__O European__B-ORG Society__I-ORG for__I-ORG Vascular__I-ORG Surgery__I-ORG guidelines__O also__O drew__O on__O the__O four__O studies__O in__O the__O Cochrane__B-PER study,__O with__O the__O MASS__B-ORG study__O the__O largest.__O
It__O supported__O population__O screening__O of__O older__O men__O to__O reduce__O `aneurysm-related__O mortality__O by__O almost__O half'.__O
(p.S5)__O (10).__O
